CeriBell (NASDAQ:CBLL) Director Josef Parvizi Sells 25,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.94, for a total transaction of $573,500.00. Following the completion of the transaction, the director directly owned 747,652 shares in the company, valued at $17,151,136.88. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $21.49, for a total transaction of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Stock Performance

NASDAQ:CBLL opened at $21.45 on Wednesday. The stock has a 50 day simple moving average of $19.53 and a 200 day simple moving average of $15.23. The stock has a market cap of $795.71 million, a P/E ratio of -14.21 and a beta of 1.02. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $26.04. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The company had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. Research analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in CeriBell by 55.4% during the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares during the period. Squarepoint Ops LLC bought a new stake in shares of CeriBell in the 2nd quarter valued at $1,054,000. Police & Firemen s Retirement System of New Jersey raised its stake in CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares during the last quarter. F m Investments LLC bought a new position in CeriBell during the second quarter worth $381,000. Finally, Peregrine Capital Management LLC boosted its position in CeriBell by 7.7% during the third quarter. Peregrine Capital Management LLC now owns 367,945 shares of the company’s stock valued at $4,228,000 after acquiring an additional 26,286 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Raymond James Financial assumed coverage on CeriBell in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock. JPMorgan Chase & Co. dropped their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. TD Cowen reduced their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Finally, Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.